News

News 11.08.2020 Zurich-Schlieren, Switzerland, August 11, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced the reservation by the Swiss Federal Office of Public Health: Bundesamt für Gesundheit (FOPH-BAG) of a defined number of initial doses...

News 22.07.2020 Schlieren (Zurich), Switzerland, July 22, 2020 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has been granted the European patent, EP 3268058, entitled ‘Osteoinductive composites’. This patent covers certain combinations of polymers and granular materials and further expands Kuros’s patent portfolio relating to its...

News 20.07.2020 Zurich-Schlieren, Switzerland, July 20, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced that Allergan, an AbbVie company, has informed Molecular Partners of their intent to withdraw application filings with both the European Medicines Agency (EMA) and the...

Events, Internal events
Event date: 21.07.2020 21. July 2020, 8:30 AM - 9:30 AM CEST Collaborating with big corporates is a good way for startups to increase their chance for a long term success. Especially in industries with high market-entrance barriers, like Pharma or MedTech, corporates can bring in essential capital, experience and industrialization-power. Nevertheless, only a...

News 09.07.2020 Zurich-Schlieren, Switzerland, July 9, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced a collaboration with AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), to support development of the company’s tri-specific...